Frith P A, Warlow C P
Department of Clinical Neurology, Radcliffe Infirmary, Oxford, U.K.
Thromb Res. 1988 Mar 1;49(5):463-70. doi: 10.1016/s0049-3848(98)90003-2.
The bleeding time was measured in 120 patients participating in a longterm randomised double-blind trial of aspirin in thromboembolic prophylaxis (UK-TIA aspirin Study). In 70 patients taking aspirin 300 mg or 1,200 mg daily for a mean duration of 35 months the bleeding time averaged 228 seconds. In comparison with 30 patients randomised to placebo and not taking aspirin whose bleeding time averaged 217 seconds, there was no significant difference. Stratification of bleeding time estimation by duration of treatment suggested no significant trend in either placebo or aspirin groups over several years. These results suggest that the longterm trials of aspirin should be looked at again from the point of view of efficacy of treatment by time from randomisation.
对120名参与阿司匹林预防血栓栓塞长期随机双盲试验(英国短暂性脑缺血发作阿司匹林研究)的患者进行了出血时间测量。70名患者每日服用300毫克或1200毫克阿司匹林,平均服用时长为35个月,其出血时间平均为228秒。相比之下,30名被随机分配到安慰剂组且未服用阿司匹林的患者,其出血时间平均为217秒,二者无显著差异。按治疗时长对出血时间评估进行分层分析表明,在数年时间里,安慰剂组和阿司匹林组均无显著趋势。这些结果表明,应从随机分组后的治疗时间疗效角度,重新审视阿司匹林的长期试验。